Omeros deal

Omeros received $20 million from private investment firm Vulcan Capital and a $5 million grant from Washington State's Life Sciences Discovery Fund to advance Omeros' preclinical G protein-coupled receptor (GPCR) discovery program. Vulcan Capital and the fund are eligible for a tiered percentage of net proceeds. Vulcan received three five-year warrants to purchase 133,333 shares each, with each warrant exercisable at $20, $30 and $40, respectively. ...